



Supplementary Figure S11. ICI-resistant BCC harbour higher levels of TME2-like CAFs and myeloid cells.

Supplementary Figure S11: ICI-resistant BCCs harbor higher levels of TME2-like CAFs and myeloid cells.

A) Expression level of canonical cell type markers in single cells from eight ICI-treated human BCCs represented as violin plots.

B) Average expression level of the STME2 signature in single cells of eight ICI-treated huBCC samples, represented as a color scale overlaid on the UMAP (left panel) and as violin plots per cell type ranked according to Fig. 6C (right panel).

C) Average expression level of the STME1 signature in single cells of eight ICI-treated huBCC samples, represented as a color scale overlaid on the UMAP (left panel) and as violin plots per cell type ranked according to Fig. 6C (right panel).

D) Average expression level of the difference between STME2 and STME1 signature scores in Fibroblasts populations of individual ICI-treated BCC samples, represented as a color scale overlaid UMAP plot.

E) Average expression level of the difference between STME2 and STME1 signature scores in Myeloid cell populations of individual ICI-treated BCC samples, represented as a color scale overlaid UMAP plot.

F) Expression level of *SPP1*, *CXCL12* and the MC3 cluster marker genes in the Myeloid cell populations of Non Responder BCC samples, represented as a color scale overlaid UMAP plot.